{"id":"cae5a75412bd","type":"article","url":"https://hartvaat.nl/2026/01/16/non-hdl-c-doelen-halen-in-de-eerste-en-tweede-lijn-een-da-vinci-deelanalyse/","title":"Non-HDL-C doelen halen in de eerste en tweede lijn: een DA VINCI-deelanalyse","title_en":"Attainment of Non-High-Density Lipoprotein Cholesterol Targets in Secondary and Primary Care: A secondary-analysis of the DA VINCI study","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","ezetimibe","niet-statine-therapie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00010-9/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00010-9/fulltext","authors":["Aksaan Arif","Irene Karungi","Christophe A.T. Stevens","Amany Elshorbagy","Kausik K. Ray","the DA VINCI study group"],"significance":5,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A secondary analysis of the European DA VINCI study assessed non-HDL-cholesterol goal attainment in primary and secondary care. Non-HDL-C provides prognostic information beyond LDL-C alone, particularly when LDL-C appears well controlled.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een secundaire analyse van de Europese DA VINCI-studie onderzocht in hoeverre non-HDL-cholesteroldoelen worden behaald bij patiënten in de eerste en tweede lijn. Non-HDL-C biedt prognostische informatie bovenop LDL-C, vooral wanneer LDL-C ogenschijnlijk goed gereguleerd is.","abstract_original":"Non-high-density lipoprotein-cholesterol (non-HDL-C) provides prognostic information on cardiovascular disease (CVD) risk, even when low-density lipoprotein-cholesterol (LDL-C) appears controlled, and is a secondary target in guidelines. We evaluated non-HDL-C goal-attainment across Europe using European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, explored factors influencing goal-attainment and assessed lipid-lowering therapy (LLT) practices."}